Senate HELP Committee chairman to outline healthcare affordability agenda
Healthcare costs remain a central policy issue in Washington as U.S. Senator Bill Cassidy prepares to present his MVP agenda on the Senate floor today. The plan centers on making care more affordable by directing money to families and patients while promoting greater price transparency.
Highlights
- Cassidy announces his MVP agenda on the Senate floor, advocating for direct-to-family healthcare funding and reduced intermediary involvement to lower costs.
- President Trump signs Cassidy's PBM Reform Act, targeting increased price transparency and stricter regulation of middlemen inflating prescription drug costs.
- Cassidy and Senator Mike Crapo champion the Health Care Freedom for Patients Act as a patient-focused alternative to continued large-scale insurance company subsidies.
Cassidy sets out patient-focused policy pitch
As reported by Senate HELP Committee, citing the Senate Committee on Health, Education, Labor, and Pensions Chairman's Newsroom, Cassidy is scheduled to speak on the U.S. Senate floor today about how his MVP agenda seeks to lower healthcare costs by giving money directly to families.The Louisiana Republican, who chairs the Senate HELP Committee, frames the approach around reducing the role of intermediaries in the healthcare system and increasing transparency in pricing. The committee statement says Cassidy has already used previous floor speeches to urge President Trump and Congress to work with him on lowering costs by sending money directly to patients and cutting out middlemen.
Legislative backdrop and sector implications
Cassidy's broader healthcare push builds on recent legislative action highlighted in the committee statement. President Trump recently signs Cassidy's PBM Reform Act into law, a measure aimed at increasing price transparency and cracking down on middlemen that raise prescription drug prices for patients.The statement also says Cassidy leads the Health Care Freedom for Patients Act with U.S. Senator Mike Crapo as an alternative to Democrats' plan to continue providing billions of dollars to large insurance companies. The agenda underscores continuing debate in the U.S. healthcare sector over drug pricing, insurance funding and whether direct support to patients can play a larger role in cost reduction.
Our earlier coverage of CVS Caremark’s FTC settlement focused on new limits on after-market drug rebates and an option for clients to opt out of rebate-based payment models. We also noted that the agreement would require certain TrumpRx cash purchases to count toward insurance deductibles once supporting regulations are in place—aiming to make discounts more meaningful for patients and reduce drug costs.
Latest Public Safety News
- Forex
- Crypto